Literature DB >> 18055507

International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states.

R T Jensen1, J F Battey, E R Spindel, R V Benya.   

Abstract

The mammalian bombesin receptor family comprises three G protein-coupled heptahelical receptors: the neuromedin B (NMB) receptor (BB(1)), the gastrin-releasing peptide (GRP) receptor (BB(2)), and the orphan receptor bombesin receptor subtype 3 (BRS-3) (BB(3)). Each receptor is widely distributed, especially in the gastrointestinal (GI) tract and central nervous system (CNS), and the receptors have a large range of effects in both normal physiology and pathophysiological conditions. The mammalian bombesin peptides, GRP and NMB, demonstrate a broad spectrum of pharmacological/biological responses. GRP stimulates smooth muscle contraction and GI motility, release of numerous GI hormones/neurotransmitters, and secretion and/or hormone release from the pancreas, stomach, colon, and numerous endocrine organs and has potent effects on immune cells, potent growth effects on both normal tissues and tumors, potent CNS effects, including regulation of circadian rhythm, thermoregulation; anxiety/fear responses, food intake, and numerous CNS effects on the GI tract as well as the spinal transmission of chronic pruritus. NMB causes contraction of smooth muscle, has growth effects in various tissues, has CNS effects, including effects on feeding and thermoregulation, regulates thyroid-stimulating hormone release, stimulates various CNS neurons, has behavioral effects, and has effects on spinal sensory transmission. GRP, and to a lesser extent NMB, affects growth and/or differentiation of various human tumors, including colon, prostate, lung, and some gynecologic cancers. Knockout studies show that BB(3) has important effects in energy balance, glucose homeostasis, control of body weight, lung development and response to injury, tumor growth, and perhaps GI motility. This review summarizes advances in our understanding of the biology/pharmacology of these receptors, including their classification, structure, pharmacology, physiology, and role in pathophysiological conditions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18055507      PMCID: PMC2517428          DOI: 10.1124/pr.107.07108

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  481 in total

1.  Bombesin enhancement of cAMP accumulation in Swiss 3T3 cells: evidence of a dual mechanism of action.

Authors:  J B Millar; E Rozengurt
Journal:  J Cell Physiol       Date:  1988-11       Impact factor: 6.384

2.  MicroPET imaging of breast cancer using radiolabeled bombesin analogs targeting the gastrin-releasing peptide receptor.

Authors:  Jesse J Parry; Rebecca Andrews; Buck E Rogers
Journal:  Breast Cancer Res Treat       Date:  2006-07-13       Impact factor: 4.872

Review 3.  Mammalian bombesin receptors.

Authors:  G S Kroog; R T Jensen; J F Battey
Journal:  Med Res Rev       Date:  1995-09       Impact factor: 12.944

4.  Mechanism of [Tyr4]bombesin-induced desensitization in dispersed acini from guinea pig pancreas.

Authors:  S J Pandol; R T Jensen; J D Gardner
Journal:  J Biol Chem       Date:  1982-10-25       Impact factor: 5.157

5.  Rational design of a peptide agonist that interacts selectively with the orphan receptor, bombesin receptor subtype 3.

Authors:  S A Mantey; D H Coy; T K Pradhan; H Igarashi; I M Rizo; L Shen; W Hou; S J Hocart; R T Jensen
Journal:  J Biol Chem       Date:  2000-12-08       Impact factor: 5.157

6.  Comparative study of in vitro and in vivo activities of bombesin pseudopeptide analogs modified on the C-terminal dipeptide fragment.

Authors:  J Azay; C Nagain; M Llinares; C Devin; J A Fehrentz; N Bernad; C Roze; J Martinez
Journal:  Peptides       Date:  1998       Impact factor: 3.750

Review 7.  Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy.

Authors:  D B Cornelio; R Roesler; G Schwartsmann
Journal:  Ann Oncol       Date:  2007-03-09       Impact factor: 32.976

8.  Gq-mediated activation of c-Jun N-terminal kinase by the gastrin-releasing peptide-preferring bombesin receptor is inhibited upon costimulation of the Gs-coupled dopamine D1 receptor in COS-7 cells.

Authors:  Anthony S L Chan; Yung H Wong
Journal:  Mol Pharmacol       Date:  2005-08-01       Impact factor: 4.436

9.  The gastrin-releasing peptide receptor is rapidly phosphorylated by a kinase other than protein kinase C after exposure to agonist.

Authors:  G S Kroog; E Sainz; P J Worland; M A Akeson; R V Benya; R T Jensen; J F Battey
Journal:  J Biol Chem       Date:  1995-04-07       Impact factor: 5.157

10.  Functional properties of two bombesin-like peptide receptors revealed by the analysis of mice lacking neuromedin B receptor.

Authors:  H Ohki-Hamazaki; Y Sakai; K Kamata; H Ogura; S Okuyama; K Watase; K Yamada; K Wada
Journal:  J Neurosci       Date:  1999-02-01       Impact factor: 6.167

View more
  172 in total

1.  Pharmacokinetics and pharmacodynamics of MK-5046, a bombesin receptor subtype-3 (BRS-3) agonist, in healthy patients.

Authors:  Marc L Reitman; Victor Dishy; Allison Moreau; William S Denney; Chengcheng Liu; Walter K Kraft; Alex V Mejia; Mark A Matson; S Aubrey Stoch; John A Wagner; Eseng Lai
Journal:  J Clin Pharmacol       Date:  2011-12-12       Impact factor: 3.126

2.  Expression of CRABP1, GRP, and RERG mRNA in clinically non-functioning and functioning pituitary adenomas.

Authors:  T Chile; M L Corrêa-Giannella; M A H Z Fortes; M D Bronstein; M B Cunha-Neto; D Giannella-Neto; R R Giorgi
Journal:  J Endocrinol Invest       Date:  2011-01-26       Impact factor: 4.256

3.  Development of hypoxia enhanced 111In-labeled Bombesin conjugates: design, synthesis, and in vitro evaluation in PC-3 human prostate cancer.

Authors:  Nilesh K Wagh; Zhengyuan Zhou; Sunny M Ogbomo; Wen Shi; Susan K Brusnahan; Jered C Garrison
Journal:  Bioconjug Chem       Date:  2012-02-16       Impact factor: 4.774

4.  Pharmacology of putative selective hBRS-3 receptor agonists for human bombesin receptors (BnR): affinities, potencies and selectivity in multiple native and BnR transfected cells.

Authors:  Veronica Sancho; Terry W Moody; Samuel A Mantey; Alessia Di Florio; Hirotsugu Uehara; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2010-05-12       Impact factor: 3.750

5.  Exploring new frontiers in molecular imaging: Emergence of Ga PET/CT.

Authors:  Eik Hock Tan; Soon Whatt Goh
Journal:  World J Radiol       Date:  2010-02-28

6.  A nociceptive signaling role for neuromedin B.

Authors:  Santosh K Mishra; Sarah Holzman; Mark A Hoon
Journal:  J Neurosci       Date:  2012-06-20       Impact factor: 6.167

7.  The role of central gastrin-releasing peptide and neuromedin B receptors in the modulation of scratching behavior in rats.

Authors:  Pin-Yen Su; Mei-Chuan Ko
Journal:  J Pharmacol Exp Ther       Date:  2011-03-18       Impact factor: 4.030

8.  Identification of genes regulated by the EWS/NR4A3 fusion protein in extraskeletal myxoid chondrosarcoma.

Authors:  Christine Filion; Yves Labelle
Journal:  Tumour Biol       Date:  2012-05-18

9.  Unidirectional cross-activation of GRPR by MOR1D uncouples itch and analgesia induced by opioids.

Authors:  Xian-Yu Liu; Zhong-Chun Liu; Yan-Gang Sun; Michael Ross; Seungil Kim; Feng-Fang Tsai; Qi-Fang Li; Joseph Jeffry; Ji-Young Kim; Horace H Loh; Zhou-Feng Chen
Journal:  Cell       Date:  2011-10-14       Impact factor: 41.582

Review 10.  Radiolabeled regulatory peptides for imaging and therapy.

Authors:  Prasant K Nanda; Stephanie R Lane; Lauren B Retzloff; Usha S Pandey; Charles Jeffrey Smith
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2010-02       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.